Many adults are diagnosed with dementia at later stages or not diagnosed at all, despite how critical early detection is. Why is this the case? Dr. Chin discusses a recent article that highlights some key reasons for this trend and shares an exciting announcement.
Receiving a diagnosis of Alzheimer’s disease or a related dementia can be a complicated experience. While some experience relief at being able to put a name to their concerns, many worry about telling loved ones or being treated differently due to the stigma surrounding the word “dementia.” Mike Zuendel joins the podcast to share his experience of being diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and how he’s pushing back against the stigma surrounding dementia. He also talks about how early detection and treatment have allowed him to lead a normal life with cognitive impairment.
Guest: Mike Zuendel, member, board of directors, Banner Alzheimer’s Institute Foundation, member, Alzheimer’s Patient Advisory Board, Center for Information and Study on Clinical Research Participation, founder, Initiative to Change the D-Word, founder, CEO, Legacy Bridge Private Family Offices
What exactly does a mild cognitive impairment (MCI) diagnosis mean, and what should you do after receiving one? Hearing this diagnosis from a doctor can bring up a lot of emotions and questions for individuals and family members. Jennifer McAlister joins Dementia Matters to offer advice for next steps after receiving an MCI diagnosis and share strategies and resources that have been successful for individuals she’s worked with over the course of her career.
Guest: Jennifer McAlister, outreach and partnerships manager, Outreach, Recruitment & Engagement Core, Wisconsin Alzheimer’s Disease Research Center
While there are many kinds of dementia, like Alzheimer’s disease and Lewy body dementia, there’s one that researchers have only recently identified. LATE, or Limbic-predominant Age-related TDP-43 Encephalopathy, is a newly-characterized type of dementia associated with abnormal clumps of a protein called TDP-43. So, what exactly do we know about LATE? Dr. David Wolk joins the podcast to share what key features of LATE are, how it compares to Alzheimer’s disease and impacts treatment, and what next steps are needed to better understand this neurodegenerative disease.
Guest: David Wolk, MD, director, Penn Alzheimer’s Disease Research Center, co-director, Penn Memory Center, co-director, Penn Institute on Aging, chief, Division of Cognitive Neurology, professor of neurology, University of Pennsylvania Perelman School of Medicine
The field of biomarkers is constantly evolving, leading to developments in diagnosing and treating different kinds of dementia, but what exactly are biomarkers and how has our understanding of these measures changed over time? Dr. Henrik Zetterberg joins Dementia Matters to talk about the latest updates in research on fluid biomarkers. Dr. Zetterberg goes in depth on the role and properties of different biomarkers and how new measures and tools, like blood tests, are impacting diagnostic tests for Alzheimer’s and other neurodegenerative diseases.
Guest: Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, University College London, visiting professor, University of Wisconsin–Madison, Biomarker Core co-leader, Wisconsin Alzheimer’s Disease Research Center
Dr. Reisa Sperling returns for another episode of Dementia Matters. After covering her research focused on preclinical Alzheimer’s disease in part one, Dr. Sperling dives deeper into the different factors that can impact cognitive decline and early-stage Alzheimer’s disease and how clinical trials are shaping the field’s understanding of detecting, treating and preventing the disease.
Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School
What if there was a way to detect Alzheimer’s disease before clinical signs and symptoms even appeared? Dr. Reisa Sperling joins Dementia Matters for a two-part series covering her research on detecting and treating Alzheimer’s disease at the earliest possible stage, known as preclinical Alzheimer’s. In this episode, Dr. Sperling goes in-depth on amyloid and tau proteins and the implications on early detection and treatment strategies for Alzheimer’s disease.
Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School
On this episode of Dementia Matters, Dr. Scott Roberts talks about disclosing genetic test results for APOE, a gene that can increase one’s likelihood of developing Alzheimer’s disease. While this information can be concerning, Dr. Roberts shares that it can empower individuals to take the necessary precautions to lower their risk of developing the disease. He discusses the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study, walks us through the APOE disclosure process and shares how it is evolving with the development of new Alzheimer’s treatments.
Guest: Scott Roberts, PhD, interim chair, professor of health behavior & health education, University of Michigan School of Public Health
Dementia Matters Special Series: Voices of Research Participants
What do you do if you have a family history of dementia and are experiencing symptoms, but can’t get a diagnosis? Dr. Sara Langer has dealt with just that. In the latest episode of our Voices of Research Participants series, Dr. Langer shares the obstacles she endured to receive her diagnosis of Lewy body dementia (LBD), how her background as a neurologist influenced her search for clinical care and how she turned to dementia research to find answers. She also discusses ways that the field of dementia research could improve to support those with other forms of dementia outside of Alzheimer’s disease.
Guest: Sara Langer, MD, neurologist
Co-host: Sarah Walter, MSc, program administrator, Alzheimer’s Clinical Trials Consortium (ACTC) and Alzheimer’s Therapeutic Research Institute (ATRI)
Alzheimer’s Disease International’s World Alzheimer’s Report 2021 recently found that 75% of people with dementia are undiagnosed, equating to 41 million people across the globe. The report, subtitled “Journey through the diagnosis of dementia,” also found clinician stigma is still a major barrier to diagnosis, and one in three believe nothing can be done about dementia. Dr. Serge Gauthier, co-author of the report, joins the podcast to discuss these findings, recommendations for improving dementia diagnoses, and more from the report.
Guest: Serge Gauthier, CM, MD
For individuals concerned with memory loss, the first few steps for screening and diagnosis can be the most intimidating. Dr. Cynthia Carlsson discusses recent progress in Alzheimer’s disease research, health disparities some groups face with the disease, and advice for individuals and caregivers who have concerns about memory loss.
Guest: Cynthia Carlsson, MD, MS, professor, University of Wisconsin School of Medicine and Public Health, and director, Wisconsin Alzheimer’s Institute
Frontotemporal dementia (FTD) is a type of dementia caused by degeneration in the temporal and frontal lobes of the brain. Our guest discusses the symptoms, risk factors, prevalence, and course of the disease, along with information on how a doctor diagnoses FTD and what families and caregivers can do after diagnosis.
Guest: Howard “Howie” Rosen, MD, behavioral neurologist at the University of California San Francisco Memory and Aging Center
People diagnosed with Alzheimer’s disease before the age of 65 are said to have early-onset Alzheimer’s disease. While this diagnosis is rare, the condition is very serious for the patient and their loved ones. Our guest helps define the disease and its symptoms, walks listeners through a diagnosis, and points to unique considerations for patients and their caregivers.
Guest: Susanne Seeger, MD, associate professor (clinical) of neurology, University of Wisconsin School of Medicine and Public Health
Alzheimer’s disease-related changes occur in the brain more than 15 years before a person experiences the memory and personality changes associated with the disease. By studying the disease in its earliest stages, scientists hope to find treatments that can prevent or delay the onset of dementia and memory loss.
Guest: Sterling Johnson, PhD, Clinical Neuropsychologist, Professor of Geriatrics, University of Wisconsin School of Medicine and Public Health, Associate Director of the Wisconsin Alzheimer’s Disease Research Center, Principle Investigator of the Wisconsin Registry for Alzheimer’s Prevention (WRAP) Study